FDA Posts Draft Guidance on Drug Pre-Approval Importation Requests
The Food and Drug Administration is asking for comments by Sept. 23 on a newly-posted draft guidance on Pre-Launch Activities Importation Requests (PLAIR) for drugs (here). PLAIRs are used to import unapproved finished dosage form drug products when the importer…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
anticipates imminent approval of a new drug application or abbreviated new drug application. Under the PLAIR, unapproved may be imported for relabeling or reconditioning, but are considered to be detained by FDA and so cannot enter into U.S. commerce. Historically, FDA has used examined PLAIRS on a case-by-case basis, but the agency is now creating a formal program, it said. The draft guidance outlines what information should be submitted to FDA in a PLAIR, when and how a PLAIR can be submitted, and the circumstances under which FDA will grant a PLAIR.